Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- 1 May 2019
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 30 (5), 706-720
- https://doi.org/10.1093/annonc/mdz056
Abstract
No abstract availableThis publication has 70 references indexed in Scilit:
- Pazopanib versus Sunitinib in Metastatic Renal-Cell CarcinomaThe New England Journal of Medicine, 2013
- Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion SequencingThe New England Journal of Medicine, 2012
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 StudyJournal of Clinical Oncology, 2011
- Epidemiology and risk factors for kidney cancerNature Reviews Urology, 2010
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2008
- Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trialThe Lancet, 2004
- Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinomaCancer, 2003